Page 250 - Binder2

We’re taking problems that companies are spending
millions trying to solve with their existing platforms and
answering them by throwing the old platform out. There are
billion-dollar assumptions about what a biologic is.

A class of drugs that represents the future of therapeutics is
defined by many as what it can’t be. They’re hard to scale,
hard to transport, and hard to administer. Yet a platform
built on the back of plants redefines what a biologic drug is.
It's a global model that stands to bring treatment across the
globe.

What this makes possible is not just distribution at scale.
It’s biologics that go where patients are.

Grow Where You Treat

The most revolutionary feature of edible biologics may be
their localizability. Instead of manufacturing in centralized
biopharma hubs, these therapies can be grown regionally—
tailored for local needs, stored without refrigeration, and
administered without delay.

Imagine:

• A lettuce-grown antibody therapy cultivated in a
university greenhouse in Nigeria
• A rice-based tolerizing vaccine produced in
Southeast Asia and distributed through local clinics
• A duckweed-expressed enzyme therapy
developed in a modular vertical farm in Brazil

This isn’t just theoretical.
Pilot programs are already exploring these models with

248